A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
We have been chosen as Official Charity Partner of the TCS New York City Marathon for the third year. The race will take place on Sunday, November 5, 2017.
ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
Our Board of Governors has appointed Mark Roithmayr as Chief Executive Officer. Mr. Roithmayr is the first person to hold the CEO position at the ADDF.
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
On Monday, November 14, Donald Newhouse received The Charles Evans Award from the Alzheimer’s Drug Discovery Foundation (ADDF) at our Seventh Annual Fall Symposium & Luncheon "Hope on the Horizon" at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.
The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.
Alzheimer’s Drug Discovery Foundation Launches Expanded Brain Health and Dementia Prevention Website
The streamlined site separates fact from fiction and empowers people to make smarter choices for their brain health.